- API
autism prevalence studies
data.cdc.gov | Last Updated 2023-05-02T17:46:55.000ZThis data table provides a collection of information from peer-reviewed autism prevalence studies. Information reported from each study includes the autism prevalence estimate and additional study characteristics (e.g., case ascertainment and criteria). A PubMed search was conducted to identify studies published at any time through September 2020 using the search terms: autism (title/abstract) OR autistic (title/abstract) AND prevalence (title/abstract). Data were abstracted and included if the study fulfilled the following criteria: • The study was published in English; • The study produced at least one autism prevalence estimate; and • The study was population-based (any age range) within a defined geographic area.
- API
Vaccination Coverage and Exemptions among Kindergartners
data.cdc.gov | Last Updated 2024-05-24T18:03:21.000ZVaccination Coverage and Exemptions among Kindergartners • Data on school vaccination coverage and exemptions from the School Vaccination Assessment Program for kindergartners at the national and state levels. • Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/schoolvaxview/index.html
- API
NCHS - Childhood Mortality Rates
data.cdc.gov | Last Updated 2022-04-01T18:36:17.000ZThis dataset of U.S. mortality trends since 1900 highlights childhood mortality rates by age group for age at death. Age-adjusted death rates (deaths per 100,000) after 1998 are calculated based on the 2000 U.S. standard population. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years between 2000 and 2010 are revised using updated intercensal population estimates and may differ from rates previously published. Data on age-adjusted death rates prior to 1999 are taken from historical data (see References below). Age groups for childhood death rates are based on age at death. SOURCES CDC/NCHS, National Vital Statistics System, historical data, 1900-1998 (see https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm); CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov). REFERENCES 1. National Center for Health Statistics, Data Warehouse. Comparability of cause-of-death between ICD revisions. 2008. Available from: http://www.cdc.gov/nchs/nvss/mortality/comparability_icd.htm. 2. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm. 3. Kochanek KD, Murphy SL, Xu JQ, Arias E. Deaths: Final data for 2017. National Vital Statistics Reports; vol 68 no 9. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf. 4. Arias E, Xu JQ. United States life tables, 2017. National Vital Statistics Reports; vol 68 no 7. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07-508.pdf. 5. National Center for Health Statistics. Historical Data, 1900-1998. 2009. Available from: https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm.
- API
Botswana Combination Prevention Project (BCPP) - Public Release Data
data.cdc.gov | Last Updated 2022-05-24T12:45:57.000ZThe Botswana Combination Prevention Project (BCPP) was a research project conducted by the Botswana Ministry of Health (MOH), Harvard School of Public Health/Botswana Harvard AIDS Institute Partnership (BHP), and the U.S. Centers for Disease Control and Prevention (CDC). BCPP was a community randomized trial that examined the impact of prevention interventions on HIV incidence in 15 intervention and 15 control communities. The interventions included extensive HIV testing, linkage to care, and universal treatment services. To reduce HIV incidence in the intervention communities, the UNAIDS 90-90-90 goals were used: 90% of HIV-positive persons know their status; 90% of persons who know status are to be on ART; 90% of persons on ART are to be virally suppressed. The BCPP study is composed of 2 interlocking protocols: Evaluation Protocol and Intervention Protocol. The Evaluation Protocol of the BCPP evaluated the primary endpoint (HIV incidence), as well as some key related secondary endpoints. This protocol focused on the Baseline Household Survey; the HIV Incidence Cohort; and an End of Study Survey. The Intervention Protocol of the BCPP implemented the combination prevention (CP) intervention package in CPCs and measures the uptake of these interventions (expanded HIV testing and counselling, strengthened male circumcision, and expanded HIV Care and Treatment).
- API
Cumulative Influenza Vaccination Coverage, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years
data.cdc.gov | Last Updated 2024-05-03T13:59:26.000ZCumulative Influenza Vaccination Coverage, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years • These monthly flu vaccination coverage estimates for pregnant persons are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC’s Immunization Safety Office and nine integrated health care organizations.§ This system has been used annually to estimate vaccination coverage among pregnant persons. COVID-19 vaccination coverage for pregnant persons is available here. • Figure 3A. Monthly Cumulative Influenza Vaccination Coverage*, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years, United States, Data Source: Vaccine Safety Datalink • Figure 3B. Cumulative Influenza Vaccination Coverage*, by Month, Flu Season, and Race/Ethnicity, Pregnant Persons 18-49 years, United States, Data Source: Vaccine Safety Datalink • For any month’s coverage estimate, the denominator is the number of persons with a pregnancy during the current flu season (defined as August through March) beginning before or during the specified month. The numerator is the subset of the denominator who have received flu vaccination prior to, during, or after pregnancy. The denominator increases as more persons are identified as pregnant or having been pregnant during the flu season. Cumulative vaccination coverage for one month may be lower than cumulative coverage for a previous month due to addition to the denominator of persons who are less likely to have received vaccination.
- API
Tests for antibodies to trachoma PGP3 antigen
data.cdc.gov | Last Updated 2019-03-14T15:55:23.000ZThis set includes data used in a latent class model to compare testing platforms for detection of antibodies against the Chlamydia trachomatis antigen Pgp3. The analysis was published as: Latent class modeling to compare testing platforms for detection of antibodies against the Chlamydia trachomatis antigen Pgp3. Wiegand RE, Cooley G, Goodhew B, Banniettis N, Kohlhoff S, Gwyn S, Martin DL. Sci Rep. 2018 Mar 9;8(1):4232. doi: 10.1038/s41598-018-22708-9. PMID: 29523810
- API
NNDSS - Table I. infrequently reported notifiable diseases
data.cdc.gov | Last Updated 2017-01-05T16:46:43.000ZNNDSS - Table I. infrequently reported notifiable diseases - 2016. In this Table, provisional* cases of selected† infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. “Symbols and footnotes changed in week #4, please refer to the MMWR publication for the symbols/footnotes for weeks 1, 2, and 3”. Footnote: -: No reported cases N: Not reportable NA: Not available NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. * Case counts for reporting year 2016 are provisional and subject to change. Data for years 2011 through 2015 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. † This table does not include cases from the U.S. territories. Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. § Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly reports from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Not reportable in all reporting jurisdictions. Data from states where the condition is not reportable are excluded from this table, except for the arboviral diseases and influenza-associated pediatric mortality. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html. †† Office of Management and Budget approval of the NNDSS Revision #0920-0728 on January 21, 2016, authorized CDC to receive data for these conditions. CDC is in the process of soliciting data for these conditions (except Zika virus, congenital infection). CDC and the U.S. states are still modifying the technical infrastructure needed to collect and transmit data for Zika virus congenital infections. §§ Jamestown Canyon virus and Lacrosse virus have replaced California serogroup diseases. ¶¶ Data for Haemophilus influenzae (all ages, all serotypes) are available in Table II. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition. ††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§ Data for meningococcal disease (all serogroups) are available in Table II. ¶¶¶ Please refer to the MMWR publication for weekly updates to the footnote for this condition. **** Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. †††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§§ All cases reported have occurred in travelers returning from affected areas, with their sexual contacts, or infants infected in ute
- API
NNDSS - Table I. infrequently reported notifiable diseases
data.cdc.gov | Last Updated 2016-01-07T15:15:03.000ZNNDSS - Table I. infrequently reported notifiable diseases - 2015. In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnote:-: No reported cases N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. �� Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. �� Data for the Arboviral disease, Chikungunya, and Hantavirus infection disease, non-Hantavirus Pulmonary Syndrome (HPS), will be displayed in this table after the CDC obtains Office of Management and Budget Paperwork Reduction Act approval to receive data for these conditions. ** Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ��ʉ�� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the arboviral diseases, STD data, TB data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html. ���� Data for H. influenzae (all ages, all serotypes) are available in Table II. ���� Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Please refer to the MMWR publication for weekly updates to the footnote for this condition. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition. ��ʉ�ʉ�� Data for meningococcal disease (all serogroups) are available in Table II. ������ Please refer to the MMWR publication for weekly updates to the footnote for this condition. ������ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. **** Please refer to the MMWR publication for weekly updates to the footnote for this condition. See Table II for Dengue Hemorrhagic Fever.
- API
NNDSS - Table II. Giardiasis to Haemophilus influenza
data.cdc.gov | Last Updated 2016-03-03T19:42:32.000ZNNDSS - Table II. Giardiasis to Haemophilus influenza - 2014. In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (≥ 1,000 and ≤ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Data for H. influenzae (age <5 yrs serotype b, nonserotype b, and unknown serotype) are available in Table I. More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.
- API
HHS Provider Relief Fund
data.cdc.gov | Last Updated 2024-07-11T01:22:44.000ZHHS is providing support to healthcare providers fighting the coronavirus disease 2019 (COVID-19) pandemic through the bipartisan Coronavirus Aid, Relief, & Economic Security (CARES) Act; the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act, which provide a total of $178 billion for relief funds to hospitals and other healthcare providers on the front lines of the COVID-19 response. This funding supports healthcare-related expenses or lost revenue attributable to COVID-19 and ensures uninsured Americans can get treatment for COVID-19. HHS is distributing this Provider Relief Fund (PRF) money and these payments do not need to be repaid. The Department allocated $50 billion in PRF payments for general distribution to Medicare facilities and providers impacted by COVID-19, based on eligible providers' net reimbursement. HHS has made other PRF distributions to a wide array of health care providers and more information on those distributions can be found here: https://www.hhs.gov/coronavirus/cares-act-provider-relief-fund/data/index.html